
KZR Stock Forecast & Price Target
KZR Analyst Ratings
Bulls say
Kezar Life Sciences Inc. has seen increased investor confidence following the partial lifting of the clinical hold in autoimmune hemolytic anemia (AIH), indicating a positive risk-benefit profile for its lead therapeutic candidate, Zetomipzomib (KZR-616). The full removal of the clinical hold for lupus nephritis (LN) would significantly enhance this confidence and further stimulate potential clinical uptake, signaling a promising trajectory for the company’s development pipeline. Additionally, if the clinical hold in LN is lifted, it may lead to resumed development efforts, thereby broadening the commercial opportunities for Kezar's assets.
Bears say
Kezar Life Sciences Inc. has reported ongoing challenges in the execution of its clinical trials, which may potentially delay the development of its key product candidates, Zetomipzomib (KZR-616) and KZR-261. The company has also experienced increased operational costs, leading to a significant operating loss that raises concerns about its financial sustainability and ability to fund research and development in the long term. Furthermore, the lack of significant partnerships or collaborations to bolster its financial position casts doubt on its capability to navigate the competitive landscape of biotechnology effectively.
This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KZR Analyst Forecast & Price Prediction
Start investing in KZR
Order type
Buy in
Order amount
Est. shares
0 shares